Trial · NCT07910916
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Serum PCSK9 Concentration | At baseline and 4 and 8 weeks after baseline | Serum PCSK9 concentration will be measured using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be compared between the concurrent training and control groups. |
| Secondary | Change in Serum LDL Cholesterol Concentration | At baseline and 4 and 8 weeks after baseline | Serum low-density lipoprotein cholesterol (LDL-C) concentration will be assessed from fasting blood samples. Changes over time will be compared between the concurrent training and control groups. |
| Secondary | Change in Serum HDL Cholesterol Concentration | At baseline and 4 and 8 weeks after baseline | Serum high-density lipoprotein cholesterol (HDL-C) concentration will be assessed from fasting blood samples. Changes over time will be compared between the concurrent training and control groups. |
| Secondary | Change in Serum Total Cholesterol Concentration | At baseline and 4 and 8 weeks after baseline | Serum total cholesterol concentration will be measured from fasting blood samples using an enzymatic colorimetric method. Changes over time will be compared between groups. |
| Secondary | Change in Serum Triglyceride Concentration | At baseline and 4 and 8 weeks after baseline | Serum triglyceride concentration will be measured from fasting blood samples using an enzymatic colorimetric method. Changes over time will be compared between groups. |
| Secondary | Change in Fasting Serum Glucose Concentration | At baseline and 4 and 8 weeks after baseline | Fasting serum glucose concentration will be measured using an enzymatic colorimetric method. Changes over time will be compared between groups. |
| Secondary | Change in Body Weight | At baseline and 4 and 8 weeks after baseline | Body weight will be measured in kilograms (kg) using a digital scale (Tanita RD-545). |
| Secondary | Change in Body Mass Index | At baseline and 4 and 8 weeks after baseline | Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared (kg/m²). |
| Secondary | Change in Waist Circumference | At baseline and 4 and 8 weeks after baseline | Waist circumference will be measured in centimeters (cm) at the midpoint between the lowest rib and iliac crest. |
| Secondary | Change in Hip Circumference | At baseline and 4 and 8 weeks after baseline | Hip circumference will be measured in centimeters (cm) at the widest part of the hips. |
| Secondary | Change in Waist-to-Hip Ratio | At baseline and 4 and 8 weeks after baseline | Waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference. The ratio is dimensionless. |
| Secondary | Change in Waist-to-Height Ratio | At baseline and 4 and 8 weeks after baseline | Waist-to-height ratio will be calculated by dividing waist circumference by height, expressed in the same units. The ratio is dimensionless. |
| Secondary | Change in Body Fat Percentage | At baseline and 4 and 8 weeks after baseline | Body fat percentage (%) will be assessed using bioelectrical impedance analysis (Tanita RD-545). |
| Secondary | Change in Fat Mass | At baseline and 4 and 8 weeks after baseline | Total body fat mass will be assessed in kilograms (kg) using bioelectrical impedance analysis (Tanita RD-545). |
| Secondary | Change in Fat-Free Mass | At baseline and 4 and 8 weeks after baseline | Fat-free mass will be assessed in kilograms (kg) using bioelectrical impedance analysis (Tanita RD-545). |
| Secondary | Change in Muscle Mass | At baseline and 4 and 8 weeks after baseline | Muscle mass will be assessed in kilograms (kg) using bioelectrical impedance analysis (Tanita RD-545). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07910916/registered